"Sandwich" Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients

Guoqing Zhang; Beibei Yan; Yanan Guo; Hang Yang; Jindong Li

doi:10.3389/fonc.2022.952939

"Sandwich" Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients

Front Oncol. 2022 Jul 8:12:952939. doi: 10.3389/fonc.2022.952939. eCollection 2022.

Authors

Guoqing Zhang¹, Beibei Yan¹, Yanan Guo¹, Hang Yang¹, Jindong Li¹

Affiliation

¹ Department of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Abstract

EGFR TKIs are not curative, and targeted resistance inevitably results in therapeutic failure. Additionally, there are numerous uncommon EGFR mutations that are insensitive to EGFR TKIs, and there is a lack of clinical strategies to overcome these limitations. EGFR TKI and mAbs target EGFR at different sites, and a combination regimen for delaying/preventing resistance to targeted therapy or obtaining more intensive inhibition for uncommon mutations at cellular, animal and human levels has been explored. This review critically focuses on a combination strategy for uncommon EGFR mutation-positive NSCLC, and discuss the preclinical data, clinical implications, limitations and future prospects of the combination strategy.

Keywords: NSCLC; drug resistance; epidermal growth factor receptor; tyrosine kinase inhibitor; uncommon mutation.

Publication types

Review